Solar urticaria: a time-extended retrospective series of 61 patients and review of literature

Du‐Thanh, Aurélie; Debu, A.; Lalheve, Pauline; Guillot, B.; Dereure, O.; Peyron, J

doi:10.1684/ejd.2013.1933

Cited by 46 publications

(73 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Patients with solar urticaria are often unable to spend time outdoors without triggering their symptoms. In a recent retrospective case series of 61 patients with solar urticaria, 95% of the patient cohort required <15 min of sun exposure to cause an urticarial response . However, practically, patients cannot remain indoors, so UV‐resistant clothing and the use of high‐protection, broad‐spectrum sunscreen is routinely recommended …”

Section: Management Of Cindumentioning

confidence: 99%

“…Induction of tolerance in solar urticaria through phototherapy has been reported to be effective; and rush therapy with UV‐A (a rapid incremental phototherapy regimen) has also proven to be effective within 3 days . However, tolerance induction is transient, and patients require almost daily maintenance with UV‐A exposure .…”

Section: Management Of Cindumentioning

confidence: 99%

“…Therefore, second‐line treatment at higher than standard doses may be required to provide symptom relief . Patients who respond to higher (two‐fold or four‐fold) doses of non‐sedating H 1 ‐antihistamines are able to continue natural exposure to UV light, allowing them to develop a natural desensitization . A combination of therapeutic modalities and exposure prevention has demonstrated effective results.…”

Section: Management Of Cindumentioning

confidence: 99%

See 2 more Smart Citations

Management and treatment of chronic urticaria (CU)

Maurer

Church

Gonçalo

et al. 2015

Acad Dermatol Venereol

View full text Add to dashboard Cite

Developments increasing our understanding of chronic urticaria have resulted in the simplification and improvement of available treatments. Currently, many treatments target mast cell mediators, but we can now disrupt mast cell activation with the anti-IgE antibody omalizumab, which has markedly advanced the treatment landscape for patients with difficultto-treat urticaria. Current guidelines provide a framework for the management and treatment of patients with CU but, as each patient is different, knowledge and experience of specialist dermatologists and allergists are key to effective pharmacotherapy. This article reviews the different therapeutic options for patients with chronic spontaneous urticaria (also called chronic idiopathic urticaria) or chronic inducible urticaria and discusses management of special populations or special circumstances related to CU.

show abstract

Section: Management Of Cindumentioning

confidence: 99%

Section: Management Of Cindumentioning

confidence: 99%

Section: Management Of Cindumentioning

confidence: 99%

See 1 more Smart Citation

Management and treatment of chronic urticaria (CU)

Maurer

Church

Gonçalo

et al. 2015

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…Because it is complicated to examine augmentation and inhibition spectra, and the clinical importance of the spectra has not been elucidated, tests to detect the spectra may not be performed routinely in most medical facilities that examine patients with solar urticaria. Some large populations of patients with solar urticaria have been reported, including 87 cases in Scotland, 57 in Italy, 61 in France and 224 in Spain . The presence of augmentation and inhibition spectra, however, was not mentioned in these cases, raising the possibility that examination of the spectra might not have been performed.…”

Section: Discussionmentioning

confidence: 99%

Characteristics and clinical significance of augmentation spectra in solar urticaria

Uetsu

Nomura

Matsuyama

et al. 2020

The Journal of Dermatology

View full text Add to dashboard Cite

Solar urticaria has unique spectra, such as inhibition and augmentation. The clinical significance of these spectra, especially augmentation, is not well understood. Reported cases of solar urticaria with augmentation spectra are extremely rare in the published English‐language work. The purposes of this study were to evaluate the clinical features of solar urticaria with augmentation spectra and to elucidate the mechanisms and clinical importance of the spectra. We experienced 11 cases (five females, six males; mean age, 40.1 years; range, 1–74) of solar urticaria with augmentation spectra from April 2007 to July 2019. Augmentation spectra were UV‐B in three cases, UV‐A in two, visible light in four, UV‐A and UV‐B in one, and UV‐A and visible light in one. Augmentation spectra were observed before action spectra in four cases, after in six, and before and after in one. Injection of sera irradiated with action spectra and augmentation spectra in vitro induced stronger immediate reactions than those of only action spectrum‐irradiated sera in four of five cases. The results of injection tests suggested that augmentation spectra enhance the production of urticaria‐forming factor. Clinically, we observed severe urticarial reactions in four cases, including anaphylaxis in three and moderate urticarial reactions in three. These results suggest that augmentation spectra are not as rare as previously thought and that they are associated with the severity of solar urticaria. Therefore, phototesting for both augmentation and action spectra should be performed to provide appropriate guidance for patients with solar urticaria.

show abstract

“…The patient was photosensitive from a few weeks of age and was sensitive to wavelengths of 305–500 nm. Cohort studies have included paediatric cases, but they have not been described individually …”

Section: The Patients’ Medical Historiesmentioning

confidence: 99%